نتایج جستجو برای: sofosbuvir

تعداد نتایج: 1451  

Journal: :Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2018
Muhammad Shoaib Siddique Alvia Saad Sana Shoaib

OBJECTIVE To determine the change in rapid virological response for chronic hepatitis C by qualitative PCR testing after treatment with sofosbuvir. STUDY DESIGN A descriptive study. PLACE AND DURATION OF STUDY Memon Medical Institute Hospital, Karachi, from January to September 2016. METHODOLOGY The study population consisted of patients above 18 years, till 80 years of age, of both gende...

Journal: :Journal of hepatology 2015
Peter J Ruane Dani Ain Richard Stryker Raymond Meshrekey Mina Soliman Peter R Wolfe Joseph Riad Sameh Mikhail Kathryn Kersey Deyuan Jiang Benedetta Massetto Brian Doehle Brian J Kirby Steven J Knox John G McHutchison William T Symonds

BACKGROUND & AIMS We conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin in patients of Egyptian ancestry, chronically infected with genotype 4 hepatitis C virus (HCV). METHODS Treatment-naive and previously treated patients with genotype 4 HCV were randomly allocated in a 1:1 ratio to rec...

2016
Vinay Sundaram Kris V Kowdley

Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-related mortality throughout the world. Among the six HCV genotypes, genotype 1 was significantly more aggressive when utilizing the combination of pegylated interferon and ribavirin, as genotype 1-infected patients had the lowest likelihood of achieving cure (40%-50%) and required twice as long duration of ...

Journal: :Journal of hepatology 2014
Tarik Asselah

BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS: In this open-label study, we initially randomly assigned 44 previously untreated pa...

Journal: :Journal of health organization and management 2016
Katharina Kieslich Jeonghoon Ahn Gabriele Badano Kalipso Chalkidou Leonardo Cubillos Renata Curi Hauegen Chris Henshall Carleigh B Krubiner Peter Littlejohns Lanting Lu Steven D Pearson Annette Rid Jennifer A Whitty James Wilson

Purpose - New hepatitis C medicines such as sofosbuvir underline the need to balance considerations of innovation, clinical evidence, budget impact and equity in health priority-setting. The purpose of this paper is to examine the role of public participation in addressing these considerations. Design/methodology/approach - The paper employs a comparative case study approach. It explores the ex...

Journal: :Hepatitis Monthly 2021

Background: Hepatitis C virus (HCV) can lead to increased mortality, disability, and liver transplantation if left untreated, it is associated with a possible increase in disease burden the future, all of which would surely have significant impact on health system. New antiviral regimens are effective treatment yet expensive. Objectives: The purpose present study was assess cost-effectiveness t...

Journal: :Journal of Pakistan Medical Association 2023

Objective: To assess cardiovascular risk after sofosbuvir and daclatasvir antiviral combination therapy in chronic hepatitis C virus patients.Methods: The prospective cohort study was conducted at the Kafrelsheikh University Hospital, Egypt, from December 2019 to 2021, comprised adult patients of either gender with minimum ejection fraction 40%. They were classified into groups according their ...

2017
Fazia Mir Alp S Kahveci Jamal A Ibdah Veysel Tahan

Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinic...

2016
Yuki Ohta Tatsuo Kanda Tatsuro Katsuno Shin Yasui Yuki Haga Reina Sasaki Masato Nakamura Shuang Wu Shingo Nakamoto Makoto Arai Osamu Yokosuka

BACKGROUND Ulcerative colitis is a lifelong, immunologically mediated disease. Direct-acting antivirals (DAAs) are now available for the treatment of chronic hepatitis C virus (HCV) infection. An interferon-free regimen appears useful, safe and effective for many patients for whom interferon-based treatment is contraindicated. CASE PRESENTATION We studied a 56-year-old treatment-naïve Japanes...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید